Dr. Falk Pharma GmbH
Industry / private company
Location:
Freiburg,
Germany (DE)
ISNI: 0000000404935305
ROR: https://ror.org/05sh9vm75
Show on Map:
Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease (2024)
Dotsenko V, Tewes B, Hils M, Pasternack R, Isola J, Taavela J, Popp A, et al.
Journal article
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial (2022)
Kruis W, Siegmund B, Lesniakowski K, Simanenkov V, Khimion L, Sobon M, Delmans G, et al.
Journal article
Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme (2022)
Miehlke S, Schlag C, Lucendo AJ, Biedermann L, Vaquero CS, Schmoecker C, Hayat J, et al.
Journal article
A randomized trial of a transglutaminase 2 inhibitor for celiac disease (2021)
Schuppan D, Mäki M, Lundin KE, Isola J, Friesing-Sosnik T, Taavela J, Popp A, et al.
Journal article
norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study (2017)
Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, et al.
Conference contribution